Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) ...

Shares of Dr. Reddy’s Laboratories Ltd ADR (NYSE:RDY) climbed 3.1% in premarket trading today following the announcement of a collaboration and license agreement with Alvotech to co-develop, ...

Alvotech and Dr. Reddy's collaborate to develop biosimilar Keytruda, expanding global access to cancer treatment options.

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...

On Thursday, 2257 stocks advanced, 1725 declined and 147 remained unchanged on Bombay Stock Exchange with advance decline ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and ...

Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

Markets remained stable, with the Nifty and Sensex closing robustly despite retreating from peak intraday levels in the Thursday trading session as a recovery in the pharma and real estate sectors ...

USA-based subsidiary Vividion Therapeutics has taken over full development and commercialization rights for VVD-214, a ...

Dr. Reddy’s Laboratories shares rose 4% to Rs 1303.45 against previous close of Rs 1252.15 on BSE. Market cap of the firm ...

At about 3:10 pm, the Sensex was up 385.61 points or 0.48 percent at 81,383.86, and the Nifty was up 116.55 points or 0.47 ...